NOT-DA-19-055: Notice of Correction to Application Types Allowed for PAR-19-259, " NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional)"

Notice of Correction to Application Types Allowed for PAR-19-259, " NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional)"

Notice Number: NOT-DA-19-055

Key Dates
Release Date: June 18, 2019

Related Announcements
None

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this Notice is to change the Application Types Allowed for PAR-19-259, " NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional)".

The following section has been modified:

Section II. Award Information

Currently reads:

Application Types Allowed

New
Renewal
Resubmission
Revision

Should correctly read:

Application Types Allowed

New
Renewal - a Center may be funded for a maximum of two competitive segments
Resubmission
Revision

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Kevin Walton, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-435-0762
Email: kevin.walton@nih.gov

Meyer D. Glantz, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-6504
Email: mglantz@nida.nih.gov

Roger Little, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-435-1316
Email: Roger.Little@nih.gov

Steven Grant, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-4877
Email: sgrant@nida.nih.gov